Skip to main content

Table 2 Number of Promoters/CpG sites differentially hyper-/hypomethylated within the best 1000 combined rank

From: Differential methylation EPIC analysis discloses cisplatin-resistance related hypermethylation and tumor-specific heterogeneity within matched primary and metastatic testicular germ cell tumor patient tissue samples

 

Region level (promoters) (hyper-/hypomethylated)

Site level (CpG site) (hyper-/hypomethylated)

Histology

 NS-EC

469/38

817/183

 EC-SE

467/65

794/206

 YST/TE-EC

501/122

953/47

 YST/TE-SE

519/31

899/101

Metastasis-primary

 Patient #1

209/324

500/500

 Patient #2

321/140

405/595

 Patient #3

289/210

422/578

 Patient #4

337/73

655/345

Cisplatin resistant-sensitive

488/8

801/199